1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Intermittent Claudication Global Clinical Trials Review, H2, 2016

Intermittent Claudication Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Intermittent Claudication Global Clinical Trials Review, H2, 2016" provides an overview of Intermittent Claudication clinical trials scenario. This report provides top line data relating to the clinical trials on Intermittent Claudication. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Intermittent Claudication Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Intermittent Claudication to Cardiovascular Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Intermittent Claudication to Cardiovascular Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Intermittent Claudication Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 79
Abbreviations 79
Definitions 79
Research Methodology 80
Secondary Research 80
About GlobalData 81
Contact Us 81
Disclaimer 81
Source 82

List of Tables
Intermittent Claudication Therapeutics, Global, Clinical Trials by Region, 2016* 6
Intermittent Claudication Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Intermittent Claudication Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Intermittent Claudication Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Intermittent Claudication Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Intermittent Claudication Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Intermittent Claudication Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Intermittent Claudication Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Intermittent Claudication to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Intermittent Claudication Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Intermittent Claudication Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Intermittent Claudication to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Intermittent Claudication Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Intermittent Claudication Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Intermittent Claudication Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Intermittent Claudication Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Intermittent Claudication Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Intermittent Claudication Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Intermittent Claudication Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Intermittent Claudication Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Intermittent Claudication Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Intermittent Claudication Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Intermittent Claudication Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Intermittent Claudication Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Intermittent Claudication Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Intermittent Claudication Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Intermittent Claudication Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Intermittent Claudication Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Intermittent Claudication Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Intermittent Claudication Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Intermittent Claudication Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Intermittent Claudication to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Intermittent Claudication Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Intermittent Claudication Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Intermittent Claudication to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Intermittent Claudication Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Intermittent Claudication Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Intermittent Claudication Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Intermittent Claudication Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Intermittent Claudication Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Intermittent Claudication Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Intermittent Claudication Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Intermittent Claudication Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Intermittent Claudication Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Intermittent Claudication Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Intermittent Claudication Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 80

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Summary Hypertension is a serious and common medical condition ...

Softgel Capsules Market Analysis & Trends - Application(Health supplement, Vitamins & Dietary Supplements, CardiovascularDrugs, Anti-Inflammatory Drugs and Antibiotic & Antibacterial Drugs), End-User

Softgel Capsules Market Analysis & Trends - Application(Health supplement, Vitamins & Dietary Supplements, CardiovascularDrugs, Anti-Inflammatory Drugs and Antibiotic & Antibacterial Drugs), End-User

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Softgel Capsules Market is poised to grow at a CAGR of around 5.4% over the next decade to reach approximately $316.6 billion by 2025. Some of the prominent trends that the market is witnessing ...

Global and Chinese Adenosine (CAS 58-61-7) Industry, 2017 Market Research Report

Global and Chinese Adenosine (CAS 58-61-7) Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The 'Global and Chinese Adenosine Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Adenosine industry with a focus on the Chinese market. ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.